Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321836 | 0.92 | FOLH1 (0.50) | EPHX1FOLH1SIRT1SIRT6KDM4E | |
| SCHEMBL12508000 | 0.88 | EPHX1 (0.49) | EPHX1FOLH1SIRT1SIRT6SIRT5 | |
| SCHEMBL10017794 | 0.86 | FOLH1 (0.51) | EPHX1FOLH1SIRT1TGM2MEN1 | |
| SCHEMBL13057085 | 0.86 | FOLH1 (0.51) | EPHX1FOLH1SIRT1TGM2MEN1 | |
| SCHEMBL11428966 | 0.86 | EPHX1 (0.50) | EPHX1FOLH1SIRT1TGM2MEN1 | |
| SCHEMBL25176384 | 0.86 | EPHX1 (0.50) | EPHX1FOLH1SIRT1TGM2MEN1 | |
| SCHEMBL10075870 | 0.83 | EPHX1 (0.47) | EPHX1SIRT1SIRT6SIRT5SIRT2 | |
| SCHEMBL10167194 | 0.83 | EPHX1 (0.51) | EPHX1FOLH1SIRT1SIRT6TGM2 | |
| SCHEMBL16206243 | 0.82 | ZDHHC7 (0.44) | EPHX1SIRT1SIRT6MEN1KMT2A | |
| SCHEMBL14980111 | 0.82 | EPHX1 (0.46) | EPHX1FOLH1SIRT1SIRT6SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200867-A1 | ALKOXYLATION METHODS | NEKTAR THERAPEUTICS | 2016-07-14 | — | — | US | disclosed |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | NOVO NORDISK HEALTHCARE AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | NOVO NORDISK HEALTHCARE AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-9320808-B2 | Acid salt forms of polymer-drug conjugates and alkoxylation methods | NEKTAR THERAPEUTICS (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150105519-A1 | ACID SALT FORMS OF POLYMER-DRUG CONJUGATES AND ALKOXYLATION METHODS | NEKTAR THERAPEUTICS (US) | 2015-04-16 | — | — | US | disclosed |
| US-8383380-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2012-02-02 | — | — | US | disclosed |
| US-8084572-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110206633-A1 | POLYMER CONJUGATES OF CD-NP PEPTIDES | Nektar Therapectics (US) | 2011-08-25 | — | — | US | disclosed |
| US-20100056428-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20090215979-A1 | Process for the preparation of alkoxyamine functionalized polyethylene glycols | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215979-A1 | Process for the preparation of alkoxyamine functionalized polyethylene glycols | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-7419600-B2 | Method for purifying a branched water-soluble polymer | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080076700-A1 | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076700-A1 | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206633-A1 | POLYMER CONJUGATES OF CD-NP PEPTIDES | CD63, CLSPN, LNPEP | EPHX1 2339/4885FOLH1 350/4885SIRT1 3579/4885 |
| US-20100056428-A1 | MODIFIED PROTEINS | PTMS, CD2BP2, SIGLEC7 | EPHX1 3097/4885FOLH1 724/4885SIRT1 3175/4885 |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | SIGLEC7, FUT4, SELPLG | EPHX1 1744/4885FOLH1 195/4885SIRT1 2997/4885 |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | EPHX1 1395/4885FOLH1 565/4885SIRT1 4051/4885 |
| US-20150105519-A1 | ACID SALT FORMS OF POLYMER-DRUG CONJUGATES AND ALKOXYLATION METHODS | SLC10A1, SLC10A6, SLC38A7 | EPHX1 1556/4885FOLH1 293/4885SIRT1 3352/4885 |
| US-20080076700-A1 | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone | THOP1, GHRHR, SHBG | EPHX1 2104/4885FOLH1 473/4885SIRT1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.